CT-based AI to predict outcomes after kidney cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational cohort at Union Hospital (Wuhan) will collect pre-treatment abdominal CT scans and clinical data from adult patients who had surgery for renal cell carcinoma between August 2025 and August 2026. Radiomics features will be extracted from those CT images and used to train and validate machine-learning models to predict clinical outcomes after surgery such as recurrence or progression. The study does not alter clinical treatment and will follow patients over time to compare predicted risk with actual outcomes. Results are intended to inform personalized follow-up strategies and support clinical decision-making using noninvasive imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026;
2. Aged \> 18 years old;
3. At least one abdominal CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma.

Exclusion Criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than renal cell carcinoma;
4. Unclear pathological diagnosis.

Where it's running

• Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Lian Yang
• Email: yanglian@hust.edu.cn
• Phone: 18986273791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• QLESP Block to Ease Pain After Robot-Assisted Kidney Surgery

  Doctors are testing a ultrasound-guided nerve block called QLESP to see if it lowers pain and reduces strong pain medicines after robotic partial nephrectomy in adults.

  Recruiting Huazhong University of Science and Technology · Wuhan, Hubei · NCT07704970

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Bone density changes with anti-PD-1 immunotherapy

  This pilot will test if anti-PD-1 immunotherapy changes bone density in adults starting approved anti-PD-1 treatment for certain early-stage cancers.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07555210

• Galectin-3 levels and outcomes with PD-1/PD-L1 therapy in kidney, bladder, lung, and liver cancer

  This study tests whether blood galectin‑3 levels before treatment predict outcomes for people with kidney, bladder, lung, or liver cancer who are starting PD‑1/PD‑L1 immunotherapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv, Israel · NCT07485114

• Template lymph node surgery plus kidney removal vs kidney removal alone for high-risk kidney cancer

  In people with high-risk kidney cancer, this study tests whether removing a broader set of lymph nodes during kidney removal helps people live longer and have their cancer stay away longer compared with removing only a few affected nodes.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07321197

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.